Deprescribing in older adults during COVID-19 pandemic; Opportunity or risk?
- 1 December 2020
- journal article
- letter
- Published by Elsevier BV in Research in Social and Administrative Pharmacy
- Vol. 17 (5), 1024-1025
- https://doi.org/10.1016/j.sapharm.2020.11.016
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Barriers to conducting deprescribing in the elderly population amid the COVID-19 pandemicResearch in Social and Administrative Pharmacy, 2020
- Global approaches for global challenges: The possible support of rehabilitation in the management of COVID‐19Journal of Medical Virology, 2020
- Association of Polypharmacy With 1-Year Trajectories of Cognitive and Physical Function in Nursing Home Residents: Results From a Multicenter European StudyJournal of the American Medical Directors Association, 2018
- Polypharmacy in Home Care in Europe: Cross-Sectional Data from the IBenC StudyDrugs & Aging, 2018
- Interactions between drugs and geriatric syndromes in nursing home and home care: results from Shelter and IBenC projectsAging Clinical and Experimental Research, 2018
- Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjectsCardiovascular Diabetology, 2017
- Late-life enalapril administration induces nitric oxide-dependent and independent metabolic adaptations in the rat skeletal muscleAGE, 2012
- Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profileThe Journal of nutrition, health and aging, 2010